Medifast Plunges to Q3 Loss Amid 36% Revenue Drop

TL;DR

**MEDIFAST IS CRUMBLING, REVENUE PLUMMETING AND PROFITS GONE – SELL!**

AI Summary

Medifast, Inc. (MED) reported a significant decline in financial performance for the three and nine months ended September 30, 2025. Revenue decreased by 36.2% to $89.4 million for the three months ended September 30, 2025, compared to $140.2 million in the prior year. For the nine months, revenue fell 35.7% to $310.7 million from $483.5 million. The company swung to a net loss of $2.3 million ($0.21 per share) for the three-month period, a sharp contrast to the net income of $1.1 million ($0.10 per share) in the same period of 2024. Year-to-date, Medifast recorded a net loss of $0.6 million ($0.05 per share), down from a net income of $1.3 million ($0.12 per share) in the first nine months of 2024. Operating income also deteriorated, moving from a gain of $2.1 million to a loss of $4.1 million for the quarter. Key business changes include a substantial reduction in advertising expense, which dropped from $4.6 million to $0.7 million for the three months ended September 30, 2025. The company also saw a significant decrease in inventory, from $42.4 million at December 31, 2024, to $23.2 million at September 30, 2025, primarily due to a reduction in finished goods. Risks include the impact of new tax legislation like the One Big Beautiful Bill Act (OBBBA) on R&D deductibility and the ongoing evaluation of deferred tax asset realizability. The strategic outlook involves adapting to new accounting pronouncements like ASU 2023-07, which was adopted for interim periods in Q1 2025, and evaluating ASU 2023-09 and ASU 2024-03 for future impact.

Why It Matters

Medifast's substantial revenue decline and shift to a net loss signal significant headwinds for investors, raising concerns about the company's competitive positioning in the weight management market. The sharp reduction in advertising spending, from $4.6 million to $0.7 million, could further impact customer acquisition and market share, potentially benefiting competitors. For employees, continued financial underperformance could lead to restructuring or job insecurity. The broader market may view this as a sign of shifting consumer preferences away from direct-selling weight loss models, impacting other companies in the health and wellness direct sales sector.

Risk Assessment

Risk Level: high — The company reported a net loss of $2.26 million for the three months ended September 30, 2025, a significant deterioration from a net income of $1.13 million in the prior year. Revenue also declined sharply by 36.2% to $89.4 million from $140.2 million. This substantial financial downturn, coupled with a near break-even pre-tax position magnifying tax rate volatility, indicates high operational and financial risk.

Analyst Insight

Investors should consider divesting Medifast shares given the severe revenue contraction and net losses. The significant decline in advertising spend suggests a lack of investment in growth, which could further depress future performance. Monitor upcoming filings for any strategic shifts or signs of stabilization, but current trends are highly concerning.

Financial Highlights

revenue

$89.4M

net Income

-$2.3M

eps

-$0.21

revenue Growth

-36.2%

Key Numbers

• $89.4M — Revenue for Q3 2025 (down 36.2% from $140.2M in Q3 2024)
• $(2.26M) — Net loss for Q3 2025 (compared to net income of $1.13M in Q3 2024)
• $(0.21) — Diluted EPS for Q3 2025 (compared to $0.10 in Q3 2024)
• $310.7M — Revenue for nine months ended Sep 30, 2025 (down 35.7% from $483.5M in the prior year)
• $(0.55M) — Net loss for nine months ended Sep 30, 2025 (compared to net income of $1.29M in the prior year)
• $0.7M — Advertising expense for Q3 2025 (down from $4.6M in Q3 2024)
• $23.2M — Inventories, net as of Sep 30, 2025 (down from $42.4M as of Dec 31, 2024)
• 10,991,273 — Shares outstanding as of Oct 27, 2025 (stable compared to prior periods)

Key Players & Entities

• Medifast, Inc. (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• One Big Beautiful Bill Act (regulator) — tax legislation
• ASU 2023-07 (regulator) — Accounting Standards Update
• ASU 2023-09 (regulator) — Accounting Standards Update
• ASU 2024-03 (regulator) — Accounting Standards Update
• New York Stock Exchange (regulator) — exchange where common stock is registered

FAQ

Risk Factors

• Impact of New Tax Legislation [high — regulatory]: The 'One Big Beautiful Bill Act' (OBBBA) could negatively impact Medifast's research and development (R&D) deductibility. The company is also evaluating the realizability of its deferred tax assets, which could lead to adjustments in its tax provision.
• Reduced Advertising Spend [medium — operational]: Advertising expense was significantly reduced from $4.6 million in Q3 2024 to $0.7 million in Q3 2025. This substantial cut may have contributed to the decline in revenue and could impact future customer acquisition and brand visibility.
• Inventory Reduction [medium — operational]: Inventories decreased from $42.4 million at December 31, 2024, to $23.2 million at September 30, 2025, primarily due to a reduction in finished goods. While this can improve cash flow, it might also indicate lower anticipated sales or production adjustments.

Industry Context

The health and wellness sector, particularly direct-to-consumer models like Medifast, faces intense competition and evolving consumer preferences. Companies are increasingly focused on digital engagement and personalized solutions. The industry is also sensitive to economic conditions, as discretionary spending on health products can fluctuate.

Regulatory Implications

Medifast must navigate evolving tax legislation, such as the 'One Big Beautiful Bill Act,' which could impact R&D tax credits. Additionally, changes in accounting standards, like ASU 2023-07, require careful implementation and may affect financial reporting. The company's evaluation of deferred tax asset realizability highlights the importance of tax compliance and planning.

What Investors Should Do

1. Monitor advertising spend and its correlation with revenue trends.
2. Analyze the impact of new accounting pronouncements on financial statements.
3. Assess the company's strategy for addressing declining revenue and profitability.

Glossary

ASU 2023-07

Accounting Standards Update 2023-07 relates to the accounting for costs to acquire or fulfill a contract with a customer. It provides guidance on the capitalization and amortization of such costs. (Medifast adopted this pronouncement for interim periods in Q1 2025, indicating a change in how certain customer-related costs are recognized, potentially impacting reported expenses and profitability.)

Deferred Tax Asset Realizability

This refers to the assessment of whether a company will generate sufficient future taxable income to utilize its deferred tax assets. If realizability is uncertain, a valuation allowance may need to be established, reducing the asset's carrying value. (Medifast is evaluating this, suggesting potential future tax implications and a need for careful financial planning to ensure these assets can be utilized.)

One Big Beautiful Bill Act (OBBBA)

A hypothetical new tax legislation mentioned in the context, impacting R&D deductibility. This implies changes in tax laws that could affect a company's tax expenses and investment decisions. (The potential reduction in R&D deductibility could increase Medifast's tax burden and influence its future innovation and product development strategies.)

Year-Over-Year Comparison

Medifast Inc. has experienced a significant downturn compared to the prior year. Revenue for the three months ended September 30, 2025, plummeted by 36.2% to $89.4 million, and the company swung to a net loss of $2.3 million from a profit of $1.1 million in the same period last year. This performance decline is accompanied by a substantial reduction in advertising expenses, down from $4.6 million to $0.7 million, and a significant decrease in inventory levels. New risks related to tax legislation and the ongoing evaluation of deferred tax assets have also emerged.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share MED New York Stock Exchange

Filing Documents

• med-20250930.htm (10-Q) — 898KB
• med-20250930xexx311.htm (EX-31.1) — 9KB
• med-20250930xexx312.htm (EX-31.2) — 9KB
• med-20250930xexx321.htm (EX-32.1) — 7KB
• 0001628280-25-048332.txt ( ) — 5237KB
• med-20250930.xsd (EX-101.SCH) — 29KB
• med-20250930_cal.xml (EX-101.CAL) — 65KB
• med-20250930_def.xml (EX-101.DEF) — 134KB
• med-20250930_lab.xml (EX-101.LAB) — 489KB
• med-20250930_pre.xml (EX-101.PRE) — 325KB
• med-20250930_htm.xml (XML) — 717KB

– Financial Statements

Item 1 – Financial Statements Condensed Consolidated Statements of Operations (unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 3 Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2025 and December 31, 2024 4 Condensed Consolidated Statements of Cash Flows (unaudited) for the Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements (unaudited) 8

– Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations 18

– Quantitative and Qualitative Disclosures about Market Risk

Item 3 – Quantitative and Qualitative Disclosures about Market Risk 27

– Controls and Procedures

Item 4 – Controls and Procedures 27

– Other Information

Part II – Other Information

– Legal Proceedings

Item 1 – Legal Proceedings 28

– Risk Factors

Item 1A – Risk Factors 28

– Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 28

– Other Information

Item 5 – Other Information 28

– Exhibits

Item 6 – Exhibits 29 1 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (U.S. dollars in thousands, except per share amounts & dividend data) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Revenue $ 89,409 $ 140,163 $ 310,692 $ 483,460 Cost of sales 27,250 34,489 87,645 127,056 Gross profit 62,159 105,674 223,047 356,404 Selling, general, and administrative 66,240 103,568 229,457 354,235 Income (loss) from operations ( 4,081 ) 2,106 ( 6,410 ) 2,169 Other income (expense) Interest income 1,426 1,333 4,096 3,851 Other income (expense) ( 2 ) ( 1,861 ) 3,057 ( 3,508 ) 1,424 ( 528 ) 7,153 343 Income (loss) before provision for income taxes ( 2,657 ) 1,578 743 2,512 Provision (benefit) for income taxes ( 396 ) 449 1,296 1,222 Net income (loss) $ ( 2,261 ) $ 1,129 $ ( 553 ) $ 1,290 Earnings (loss) per share - basic $ ( 0.21 ) $ 0.10 $ ( 0.05 ) $ 0.12 Earnings (loss) per share - diluted $ ( 0.21 ) $ 0.10 $ ( 0.05 ) $ 0.12 Weighted average shares outstanding Basic 10,991 10,937 10,977 10,928 Diluted 10,991 10,971 10,977 10,959 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) (U.S. dollars in thousands) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Net income (loss) $ ( 2,261 ) $ 1,129 $ ( 553 ) $ 1,290 Other comprehensive income, net of tax: Foreign currency translation — 4 — 47 Unrealized net gains on investment securities 41 319 40 54 41 323 40 101 Comprehensive income (loss) $ ( 2,220 ) $ 1,452 $ ( 513 ) $ 1,391 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET

View Full Filing

View this 10-Q filing on SEC EDGAR